Hisamitsu Pharmaceutical Co. Inc. Announces Consolidated and Non-Consolidated Earnings Results for the First Quarter Ended May 2016; Provides Consolidated and Non-Consolidated Earnings Guidance for the Year Ending February 2017
July 07, 2016
Share
Hisamitsu Pharmaceutical Co. Inc. announced consolidated and non-consolidated earnings results for the first quarter ended May 2016. For the quarter, on consolidated basis, the company's sales were ¥38,153 million compared with ¥39,680 million a year ago. Operating profits were ¥5,744 million compared with ¥5,737 million a year ago. Recurring profits were ¥5,561 million compared with ¥5,663 million a year ago. Pretax profits were ¥6,859 million compared with ¥5,639 million a year ago. Net profits were ¥4,529 million compared with ¥3,535 million a year ago.
For the quarter, on non-consolidated basis, the company's sales were ¥28,436 million compared with ¥28,867 million a year ago. Operating profits were ¥4,598 million compared with ¥5,695 million a year ago. Recurring profits were ¥4,656 million compared with ¥6,108 million a year ago. Pretax profits were ¥5,959 million compared with ¥6,093 million a year ago. Net profits were ¥4,195 million compared with ¥4,069 million a year ago.
For the year ending February 2017, the company forecasts consolidated sales of ¥155,000 million, operating profits of ¥28,000 million, pretax profits of ¥30,300 million, net profits of ¥19,400 million, capex of ¥5,300 million, depreciation of ¥5,500 million, and goodwill amortization of ¥2,100 million.
The company forecasts non-consolidated sales of ¥119,500 million, operating profits of ¥24,500 million, pretax profits of ¥26,800 million, net profits of ¥18,000 million, capex of ¥3,700 million, depreciation of ¥3,000 million, and goodwill amortization of ¥1,100 million.
Hisamitsu Pharmaceutical Co Inc is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the manufacture, sale and supply of pharmaceuticals and related products, and the operation of over-the-counter drug (OTC) business. It is also engaged in the manufacture and sale of drugs in the United States, Brazil, Vietnam, and Indonesia, the development work in Europe, the drug marketing and sales in China and Hong Kong. It is also engaged in the urban cable television broadcasting business, Internet connection service business, non-life insurance agency business, advertising agency business and the purchase, manufacture and sale of packing materials.
Hisamitsu Pharmaceutical Co. Inc. Announces Consolidated and Non-Consolidated Earnings Results for the First Quarter Ended May 2016; Provides Consolidated and Non-Consolidated Earnings Guidance for the Year Ending February 2017